Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab

Japanese Journal of Clinical Oncology

Volumn 42, Issue 11, 2012, Pages 1035-1042

  Kobayashi, Tsutomu ^a   Tsutsumi, Yasuhiko ^a,b   Sakamoto, Natsumi ^a   Nagoshi, Hisao ^a   Yamamoto sugitani, Mio ^a   Shimura, Yuji ^a   Mizutani, Shinsuke ^a   Matsumoto, Yosuke ^a   Nishida, Kazuhiro ^a   Horiike, Shigeo ^a   Asano, Naoko ^c   Nakamura, Shigeo ^c   Kuroda, Junya ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

c MYC; Diffuse large B cell lymphoma; Double hit lymphoma; Revised international prognostic index

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84868139333     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys148     Document Type: Article

References (40)

1. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001;13:325-34.
2. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33.
3. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (RIPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with RCHOP. Blood 2007;109:1857-61.
4. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
5. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
6. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
7. Offit K, Koduru PR, Hollis R, et al. 18q21 rearrangements in diffuse large cell lymphoma: incidence and clinical significance. Br J Haematol 1989;72:178-83.
8. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994;331:74-80.
9. Barrans SL, O'Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002;117:322-32.
10. Barrans SL, Evans PA, O'Connor SJ, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 2003;9:2133-9.
11. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360-5.
12. Chenevix-Trench G, Behm FG, Westin EH. Somatic rearrangements of the MYC oncogene in primary human diffuse large-cell lymphoma. Int J Cancer 1986;38:513-6.
13. Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS. MYC rearrangements and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 1991;77:1057-63.
14. Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008;22:2226-9.
15. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci 2009;100:233-7.
16. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-7.
17. Copie-Bergman C, Gaulard P, Leroy K, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009;27:5573-9.
18. van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135-42.
19. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319-31.
20. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114:2273-9.
21. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009;23:777-83.
22. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009;94:935-43.
23. Yamazaki T, Ohno H. Double-hit lymphoma with t(8;14)(q24;q32) and t(12;14)(q24;q32) chromosomal translocations. Intern Med 2011;50:2659-62.
24. Kobayashi S, Taki T, Chinen Y, et al. Identification of IGHC?-BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia. Genes Chromosome Cancer 2011;50:207-16.
25. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
26. Campaner S, Amati B. Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance. Cell Div 2012;7:6 [Epub ahead of print].
27. Kang KW, Im YB, Go WJ, Han HK. C-myc amplification altered gene expression of ABC- and SLC-transporters in human breast epithelial cells. Mol Pharm 2009;6:627-33.
28. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990;348:331-3.
29. Nakagawa M, Tsuzuki S, Honma K, Taguchi O, Seto M. Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells. Haematologica 2011;96:1318-26.
30. Sasaki N, Kuroda J, Nagoshi H, et al. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp Hematol 2011;39:817-28.
31. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-30.
32. Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol 2008;45:S11-6.
33. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6.
34. Furman RR, Martin P, Ruan J, et al. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 2010;116:5432-9.
35. Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108. Leuk Lymphoma 2009;50:728-35.
36. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2010;22:1622-7.
37. Rigacci L, Puccini B, Cortelazzo S, et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients: a multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol 2012 [Epub ahead of print].
38. Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-7.
39. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85.
40. Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 2011;118:5506-16.